ArticleCancers2021
Genomic Characterization and Therapeutic Targeting of HPV Undetected Cervical Carcinomas.
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Genomic profiling identifies actionable DNA-repair defects in a new cervical cancer model.Scientific reports · 2026Article
- Cervical HPV-independent adenosquamous carcinoma: report of a case series.Virchows Archiv : an international journal of pathology · 2026Article
- Regulatory SNP of TERT promoter accompanied by C228T andOncology letters · 2025Article
- Retrospective analysis of treatment and prognosis for clear cell carcinoma of the uterine cervix: 15-year experience at a single institution.The journal of obstetrics and gynaecology research · 2025Article
- Immune alterations and overexpression of CTCF in endometrial carcinoma: insights from molecular subtyping.Cancer cell international · 2024Article
- MicroRNA-875-5p inhibits the growth and metastasis of cervical cancer cells by promoting autophagy and apoptosis and inhibiting the epithelial-mesenchymal transition.Frontiers in oncology · 2024Article
- GuiErBai: a potent inhibitor, exhibiting broadly antitumor effect against cervical cancerFrontiers in pharmacology · 2024Article
- FAM60A promotes osteosarcoma development and progression.Cancer medicine · 2023Article
- Reduced MHC Class I and II Expression in HPV-Negative vs. HPV-Positive Cervical Cancers.Cells · 2022Article
- Improving cervical cancer survival-A multifaceted strategy to sustain progress for this global problem.Cancer · 2022Review
- Genome-wide association study and functional follow-up identify 14q12 as a candidate risk locus for cervical cancer.Human molecular genetics · 2022Article
- Article
- Article
- Review
- Genomic Risk Factors for Cervical Cancer.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 2 countries.
Funding
Abstract
Cervical cancer tumors with undetectable HPV (HPV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.